Charlie Gourley
Professor and Honorary Consultant in Medical Oncology Clinical Director, Cancer Research UK Scotland Centre, Director, Nicola Murray Centre for Ovarian Cancer Research
- Cancer Research UK Scotland Centre
- Institute of Genetics and Cancer
- Nicola Murray Centre for Ovarian Cancer Research
Contact details
- Tel: +44 (0)131 651 8510
- Email: charlie.gourley@ed.ac.uk
Address
- Street
-
Cancer Research UK Scotland Centre
Institute of Genetics and Cancer
The University of Edinburgh
Western General Hospital
Crewe Road South - City
- Edinburgh
- Post code
- EH4 2XR
- Street
- City
- Post code
Background
Charlie graduated with Genetics and Medicine degrees from Glasgow University, UK, in 1991 and 1994, respectively. From 1998 to 2005, he trained in medical oncology at the Edinburgh Cancer Centre, UK, during which he was awarded a PhD in ovarian cancer genetics from the University of Edinburgh and an NHS Education for Scotland Clinician Scientist Award. He was appointed as Senior Lecturer in Medical Oncology at the University of Edinburgh in 2005, Reader in Medical Oncology in 2011 and Professor of Medical Oncology (Personal Chair) in 2012. He received a Scottish Senior Clinical Fellowship Award in 2010. He became Director of the Nicola Murray Centre for Ovarian Cancer Research in 2016, Clinical Director of the Cancer Research UK (CRUK) Edinburgh Centre in 2019 and Clinical Director of the Cancer Research UK Scotland Centre in 2022. He is a member of the CRUK Clinical Research Committee and the German Cancer Aid Scientific Review Committee.
Charlie’s clinical research focus is ovarian cancer clinical trials. He was UK Lead for the SOLO1 trial, which led to the first-line licence for olaparib in BRCA-mutant ovarian cancer, and for the GOG281/LOGS trial of trametinib, which is the first positive randomised controlled trial in low-grade serous ovarian cancer.
Charlie’s translational research focuses on genomic characterisation of ovarian cancer in order to facilitate the discovery of biomarkers of ovarian cancer drug sensitivity and resistance. His current priorities include whole-genome sequencing of ovarian cancer tumours from across Scotland in order to improve patient selection for novel therapies and exomic sequencing of low-grade serous ovarian cancers from patients recruited into the GOG281/LOGS study in order to improve patient selection for MEK inhibition. His research group have also recently reported a comprehensive genomic characterisation of endometrioid ovarian cancer.
-
Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome
In:
Gynecologic Oncology
Research output: Contribution to Journal › Article (Published) -
Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
In:
Scientific Reports
DOI: https://doi.org/10.1038/s41598-023-34627-5
Research output: Contribution to Journal › Article (Published) -
Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.
In:
Clinical Cancer Research
DOI: https://doi.org/10.1158/1078-0432.CCR-22-1206
Research output: Contribution to Journal › Article (Published) -
Multisite gynecologic endometrioid adenocarcinomas: Can mutation profiling be used to distinguish synchronous primary cancers from metastases?
In:
Gynecologic Oncology Reports, vol. 44, pp. 101076
DOI: https://doi.org/10.1016/j.gore.2022.101076
Research output: Contribution to Journal › Article (Published) -
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
In:
Annals of Surgical Oncology
DOI: https://doi.org/10.1245/s10434-022-12459-3
Research output: Contribution to Journal › Article (Published)